ArticleFrontiers in endocrinology2026
Selective extraocular muscle regression following tocilizumab in active thyroid associated ophthalmopathy: a 3D MRI-based retrospective study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid-associated ophthalmopathy (TAO) is an autoimmune orbital disorder characterized by orbital inflammation and hyperplasia of extraocular muscles (EOMs) and adipose tissue. Tocilizumab (TCZ) has demonstrated anti-inflammatory effects in TAO, but its ability to induce structural regression of hypertrophic EOMs has not been objectively quantified using advanced three-dimensional (3D) imaging techniques. This retrospective study aimed to evaluate the clinical and structural effects of TCZ in active moderate-to-severe TAO using quantitative 3D MRI. Methods: Twenty-four patients with active moderate-to-severe TAO who completed a standard four-dose TCZ regimen (8 mg/kg every four weeks) were enrolled. Clinical parameters (Clinical Activity Score (CAS), orbital tension, proptosis) and serum biomarkers (thyrotropin receptor antibody (TRAb), interleukin-6 (IL-6) were assessed at baseline (T1), post-treatment (T2), and at one-month follow-up (T3). Structural remodeling was quantified by measuring the cross-sectional areas (CSA) of individual EOMs and orbital fat volume (OFV) using coronal 3D modified Dixon quantitative T1-weighted MRI. Results: TCZ induced rapid inflammatory inactivation, with median CAS declining from 3 to 0 ( Conclusions: TCZ is a rapid, potent, and safe intervention for active moderate-to-severe TAO. Quantitative 3D MRI provides objective evidence that TCZ selectively induces structural regression of hypertrophic EOMs, with the superior rectus showing the most pronounced response and the medial rectus exhibiting considerable resistance, which may reflect chronic structural remodeling or fibrosis-associated changes. The significant decline in serum TRAb levels further supports the systemic immunomodulatory effects of TCZ. These findings provide imaging-based evidence for the differential structural effects of TCZ on orbital tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.